Clinical trials: Hematuria; Benign
Proteinuria
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
The primary objective of this study is to assess the impact of proteinuria on the pharmacokinetic (PK) of a single dose of ALXN1720 in participants with proteinuria.
- Trial name
- NCT05314231
- Testing
- ALXN1720
- Where
- 2 sites in South Korea
- Volunteers
- 13 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hematuria, Benign Prostatic Hyperplasia
RADA16 for Aquablation Day Case
This is a pilot proof of concept single-arm study using PuraStat following Aquablation procedure to assess reduction of hematuria to allow for same day discharge.
- Conditions
- Hematuria, Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
- Trial name
- RAD (NCT06948331)
- Testing
- PuraStat
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- NYU Langone Health
Hematuria, Retention, Urinary
Anticoagulant/Antiaggregant Use and Postoperative Bleeding Risk in Patients With Bladder Tumor and Benign Prostatic Hyperplasia
Patients who were using anticoagulant or antiaggregant medications for any reason and underwent transurethral resection of bladder tumor (TUR-BT) or transurethral resection of the prostate (TURP) or open prostatectomy (OP) due to…
- Conditions
- Hematuria, Retention, Urinary, Operative Bleeding, Blood Transfusion Complication
- Trial name
- NCT05314582
- Where
- Turkey (Türkiye)
- Volunteers
- 500 people
- Sponsor
- Bezmialem Vakif University
BPH (Benign Prostatic Hyperplasia), BPH With Symptomatic Lower Urinary Tract Symptoms
Use of PuraStat Following Aquablation to Determine if There is Change in Hematuria & Probability of Same Day Discharge
Randomized, single-blinded investigational study to assess the safety of PuraStat following the Aquablation procedure
- Trial name
- PuraStat (NCT07789041)
- Testing
- PuraStat hydrogel and the syringe
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Endeavor Health
Bladder Cancer, Hematuria; Benign
PENK Methylation Test for Detecting Bladder Cancer
The primary objective of this clinical trial is to determine the sensitivity and specificity of the EarlyTect® Bladder Cancer test for bladder cancer among patients with hematuria by comparing it to the results of cystoscopy…
- Trial name
- NCT05220189
- Testing
- EarlyTect® Bladder Cancer test
- Where
- South Korea
- Volunteers
- 1,549 people
- Sponsor
- Asan Medical Center
Alport Syndrome, Thin Basement Membrane Disease
ASF Alport Patient Registry
Alport Syndrome Foundation's (ASF's) Alport Patient Registry (the Registry) is open to individuals living with Alport syndrome in the United States (US) and US territories and outlying islands.
- Conditions
- Alport Syndrome, Thin Basement Membrane Disease, Hereditary Nephritis
- Trial name
- NCT06526741
- Testing
- Longitudinal data collection
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Alport Syndrome Foundation
Urologic Diseases, Hematuria
A Study of Ward Admissions for Haematuria
This multicenter, prospective observational study will evaluate national and international practice variations (if present) in the emergency management of patients admitted to hospital with haematuria, inform a consensus…
- Conditions
- Urologic Diseases, Hematuria, Hematuria; Benign, Bladder Cancer
- Trial name
- WASHOUT (NCT07395037)
- Testing
- Inpatient work-up and management
- Where
- United Kingdom
- Volunteers
- 1,050 people
- Sponsor
- British Urology Researchers in Surgical Training
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Alport Syndrome
Alport Syndrome Treatments and Outcomes Registry
ASTOR's primary purpose is to enroll families and patients with a history of Alport syndrome in a central registry. The information we gather will be used as a basis for studies designed to test potential treatments for Alport…
- Trial name
- ASTOR (NCT00481130)
- Where
- United States
- Volunteers
- 655 people
- Sponsor
- University of Minnesota
Bladder Cancer, Benign Prostatic Hyperplasia
Intravesical Prostatic Protrusion Mimicking Urothelial Cell Carcinoma of the Bladder
In this study, investigators aim to determine the true positivity of bladder cancer identified in the bladder base, trigone or neck on ultrasonography (USG) in patients presenting with hematuria or lower urinary tract symptoms…
- Conditions
- Bladder Cancer, Benign Prostatic Hyperplasia, Hematuria
- Trial name
- NCT05077852
- Testing
- Urethrocystoscopy
- Where
- Turkey (Türkiye)
- Volunteers
- 194 people
- Sponsor
- Ankara Training and Research Hospital
Alport Syndrome, Hereditary Kidney Disease
Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
The hereditary type IV collagen disease Alport syndrome leads to kidney failure early in life. Currently there are no specific medications approved for treatment, however, several therapies have been evaluated preclinically and…
- Conditions
- Alport Syndrome, Hereditary Kidney Disease, Pediatric Kidney Disease, Thin Basement Membrane Disease
- Trial name
- Alport-XXL (NCT02378805)
- Testing
- ACE-inhibitor, Angiotensin-receptor blocker (ARB), HMG-Coenzyme inhibitor (statin)
- Where
- Germany
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- University Hospital Goettingen
Alport Syndrome, Thin Basement Membrane Disease
Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients With Alport Syndrome (COMBINE-ALPORT)
Alport syndrome (AS) is one of the most common monogenic kidney disorders, oftentimes leading to end-stage kidney disease (ESKD).
- Conditions
- Alport Syndrome, Thin Basement Membrane Disease, Alport Nephropathy
- Trial name
- COMBINE-ALPORT (NCT06499948)
- Testing
- Treatment with Spironolactone followed by Dapagliflozin followed by their combination, Treatment with Dapagliflozin followed by Spironolactone followed by their combination
- Where
- Romania
- Volunteers
- 12 people
- Sponsor
- Stefan Lujinschi
Bladder Cancer, Benign Prostate Hyperplasia
The Effect of Preemptive Analgesia On The Comfort Of Patient and Doctor, in Cystoscopy
The study was designed as a prospective, randomized double-blind placebo controlled trial. According to power analysis in regards of previous studies in the literature with diclofenac sodium, using a total of 144 patients are…
- Conditions
- Bladder Cancer, Benign Prostate Hyperplasia, Hematuria, Pain
- Trial name
- NCT03831321
- Testing
- Diclofenac Sodium, Cystoscopy, Lubricant Gel
- Where
- Turkey (Türkiye)
- Volunteers
- 144 people
- Sponsor
- Taha Uçar